About: Clinical significance of high-dose cytarabine added to cyclophosphamide/total-body irradiation in bone marrow or peripheral blood stem cell transplantation for myeloid malignancy

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Clinical significance of high-dose cytarabine added to cyclophosphamide/total-body irradiation in bone marrow or peripheral blood stem cell transplantation for myeloid malignancy Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Clinical significance of high-dose cytarabine added to cyclophosphamide/total-body irradiation in bone marrow or peripheral blood stem cell transplantation for myeloid malignancy
Creator	Fukuda, Takahiro Aoki, Kazunari Arai, Yasuyuki Eto, Tetsuya Hashimoto, Hisako Iwato, Koji Kanda, Yoshinobu Kato, Chiaki Kondo, Tadakazu Kurokawa, Mineo Ota, Shuichi Ozawa, Yukiyasu Takeda, June
Source	PMC
abstract	BACKGROUND: Addition of high-dose cytarabine (HDCA) to the conventional cyclophosphamide/total-body irradiation (CY/TBI) regimen significantly improved prognosis after cord blood transplantation (CBT) for adult acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). The efficacy of HDCA in bone marrow or peripheral blood stem cell transplantation (BMT/PBSCT), however, has not yet been elucidated. FINDINGS: We conducted a cohort study to compare the prognosis of HDCA/CY/TBI (N = 435) and CY/TBI (N = 1667) in BMT/PBSCT for AML/MDS using a Japanese transplant registry database. The median age was 38 years, and 86.0 % of the patients had AML. Unrelated donors comprised 54.6 %, and 63.9 % of donors were human leukocyte antigen (HLA)-matched. Overall survival (OS) was not improved in the HDCA/CY/TBI group (adjusted hazard ratio (HR), 1.14; p = 0.13). Neutrophil engraftment was inferior (HR, 0.80; p < 0.01), and the incidence of hemorrhagic cystitis and thrombotic microangiopathy increased in HDCA/CY/TBI (HR, 1.47 and 1.60; p = 0.06 and 0.04, respectively), leading to significantly higher non-relapse mortality (NRM; HR, 1.48; p < 0.01). Post-transplant relapse and tumor-related mortality were not suppressed by the addition of HDCA. CONCLUSIONS: This study indicated the inefficacy of HDCA/CY/TBI in BMT/PBSCT for AML/MDS. Our results should be validated in large-scale prospective studies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13045-015-0201-x) contains supplementary material, which is available to authorized users.
has issue date	2015-09-04(xsd:dateTime)
bibo:doi	10.1186/s13045-015-0201-x
bibo:pmid	26337829
has license	cc-by
sha1sum (hex)	afabc35bb3e8013fd3fd54e767176744f5b36fc7
schema:url	https://doi.org/10.1186/s13045-015-0201-x
resource representing a document's title	Clinical significance of high-dose cytarabine added to cyclophosphamide/total-body irradiation in bone marrow or peripheral blood stem cell transplantation for myeloid malignancy
has PubMed Central identifier	PMC4559384
has PubMed identifier	26337829
schema:publication	J Hematol Oncol
resource representing a document's body	covid:afabc35bb3e8013fd3fd54e767176744f5b36fc7#body_text
is schema:about of	named entity 'TBI' named entity 'AML' named entity 'conducted' named entity 'matched' named entity 'TBI' named entity 'total-body irradiation' named entity 'cytarabine' covid:arg/afabc35bb3e8013fd3fd54e767176744f5b36fc7 named entity 'human leukocyte antigen (HLA)' named entity 'MDS' named entity 'bone marrow transplantation' named entity 'leukemia cells' named entity 'potential complications' named entity 'hemorrhagic cystitis' named entity 'CNS' named entity 'Relapse' named entity 'cytotoxicity' named entity 'performance status' named entity 'TBI' named entity 'BMT' named entity 'ABO blood type' named entity 'BMT' named entity 'GVHD' named entity 'tumor' named entity 'acute phase' named entity 'GVHD' named entity 'cord blood' named entity 'relapse' named entity 'total-body irradiation' named entity 'anti-leukemic' named entity 'BMT' named entity 'BMT' named entity 'MDS' named entity 'relapse' named entity 'HLA' named entity 'TBI' named entity 'Declaration of Helsinki' named entity '0.01' named entity 'prognosis' named entity 'MDS' named entity 'Overall' named entity 'relapse' named entity 'prospective studies' named entity 'cyclophosphamide' named entity '0.01' named entity '0.80' named entity 'myelodysplastic syndrome' named entity 'CBT' named entity 'prognosis' named entity 'peripheral blood stem cell transplantation' named entity 'cyclophosphamide' named entity 'malignancy' named entity 'myeloid' named entity 'conditioning regimens' named entity 'AML' named entity 'granulocyte colony stimulating factor' named entity 'cyclosporine' named entity 'HLA' named entity 'tacrolimus' named entity 'erythrocytes' named entity 'CBT' named entity 'infection' named entity 'GVHD' named entity 'anti-leukemic' named entity 'virus' named entity 'hazard ratio' named entity 'methotrexate' named entity 'leukemia' named entity 'G-CSF'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software